期刊文献+

持续药泵化疗联合放射治疗大肠癌的临床观察

下载PDF
导出
摘要 目的评价持续药泵化疗联合放射治疗大肠癌的疗效与毒副作用。方法经病理证实的中晚期大肠癌80例,随机分为两组:实验组采用持续药泵化疗及放射治疗,对照组采用普通静脉化疗加放射治疗,药物均为国产5-氟脲嘧啶、亚叶酸钙(CF)、奥沙利铂,放射剂量为60-70Gy。结果有效(完全缓解加部分缓解)率:实验组52.5%,对照组45.0%;生存期:实验组有效缓解期6-12月,中位期6.5个月,对照组有效缓解期2-6月,中位期3个月;两组的不良反应主要为腹泻、食欲不振、中性粒细胞减少,在I-Ⅱ度之间,经对症处理后能恢复。结论持续药泵化疗联合放射治疗大肠癌,疗效确切,不良反应小,是大肠癌治疗的有效方法。
出处 《临床和实验医学杂志》 2009年第5期71-71,74,共2页 Journal of Clinical and Experimental Medicine
  • 相关文献

参考文献1

二级参考文献35

  • 1Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000:Cancer Incidence, Mortality and Prevalence Worldwide [R],Version 1.0. IARC Cancer Base No. 5. Lyon: IARC 2001.
  • 2Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ ,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol. 2003,21:60-65.
  • 3Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase Ⅱ trial[J]. J Clin Oncol. 2005,23:3697-3705.
  • 4Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med. 2004,350:2335-2342.
  • 5Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study(ahst) [J]. Proc Am Soc Clin Oncol. 2006,24:18s.
  • 6Giantonio BJ, Catalano PJ, Meropol, NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study 3200 [J]. J Clin Oncol. 2005,23:1s.
  • 7Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase Ⅲ study in patients with previously treated metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM2) (abst) [J]. Proc Am Soc Clin Oncol,2006,24: 18s.
  • 8Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha,and EGF-R in human colorectal adenocarcinoma [J]. Acta Oncol, 1998,37:285-289.
  • 9Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2,ERB B3 ) in colorectal adenocarcinomas and adenomas [J].Tumour Biol 2000,21:105-115.
  • 10Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies[J]. Crit Rev Oncol Hematol 1995,19: 183-232.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部